KDM1A and hepatocellular carcinoma: Zhang (2020) indicated that API (50, 100 μM) can inhibit the proliferation and growth of HCC cells by targeting KDM1A to regulate lipid metabolism. Moreover, the abnormal overexpression of long non-coding RNA H19 is closely related to the occurrence and progression of HCC (Zhang et al., 2019). Interestingly, Pan et al. (2021) revealed that API (50 mg/kg) can downregulate H19 and reduce the expression of β-catenin, leading to the inactivation of the Wnt/β-catenin signaling pathway, thereby inhibiting tumor growth.